title: In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
abstract: Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and methicillin resistant Staphylococcus aureus (MRSA) are important nosocomial pathogens. This study reports the in vitro activity of tigecycline against 573 and 482 ESBL-producing Enterobacteriaceae and MRSA isolates, respectively. More than 94% of all tested isolates were susceptible to tigecycline; MIC(90) found was 0.25 to 2 mg/L for ESBL-producing Enterobacteriaceae and was 0.125 mg/L for MRSA. Tigecycline demonstrated excellent in vitro activity against a wide spectrum of nosocomial pathogens.
authors: Departamento de Diagnóstico Epidemiológico, Instituto Nacional de Salud Pública, 62100, Cuernavaca, Morelos, México. jsilva@insp.mx
authors: Jesus
authors: J
authors: Silva-Sanchez
authors: Fernando
authors: F
authors: Reyna-Flores
authors: Ma Elena
authors: ME
authors: Velazquez-Meza
authors: Teresa
authors: T
authors: Rojas-Moreno
authors: Arturo
authors: A
authors: Benitez-Diaz
authors: Alejandro
authors: A
authors: Sanchez-Perez